Total synthesis of the proposed structure of iriomoteolide-1a
作者:Jun Xie、Yuelong Ma、David A. Horne
DOI:10.1016/j.tet.2011.07.066
日期:2011.9
Full details of the total synthesis of the proposed structure of iriomoteolide-1a (1) are described. The key steps include (i) a Sakurai reaction between allylsilane 11 and aldehyde 10 that bears both a tertiary chiral center and vinyl iodide moiety (ii) an anti-aldol reaction to construct the C18/C19 chiral centers (iii) a B-alkyl Suzuki-Miyaura coupling reaction to assemble the C7-C23 fragment, and (iv) a macrocyclic ring-closing metathesis to complete the construction of the target molecule. Two different approaches to access penultimate precursor 2 are delineated. The NMR spectra of the synthetic iriomoteolide-1a (1) were found not to match those reported for the natural product bringing into question its true structural identity. (C) 2011 Elsevier Ltd. All rights reserved.
Asymmetric Synthesis of the C(7)−C(23) Fragment of Iriomoteolide-1a
作者:Jun Xie、Yuelong Ma、David A Horne
DOI:10.1021/ol902110a
日期:2009.11.5
An efficient synthesis of the C(7)-C(23) fragment 2 of iriomoteolide-1a (1) has been accomplished via a B-alkyl Suzuki-Miyaura cross-coupling reaction followed by deprotection and cyclization to form the cyclic hemiketal core.
BLOODWORTH, A. J.;CURTIS, RICHARD J.;MISTRY, NAVIN, J. CHEM. SOC. CHEM. COMMUN.,(1989) N4, C. 954-955
作者:BLOODWORTH, A. J.、CURTIS, RICHARD J.、MISTRY, NAVIN
DOI:——
日期:——
COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
申请人:AMGEN INC.
公开号:US20210230189A1
公开(公告)日:2021-07-29
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.